Antonio Picardi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2504858/publications.pdf

Version: 2024-02-01

153 papers 3,409 citations

30 h-index 51 g-index

154 all docs

154 docs citations

154 times ranked

5284 citing authors

#	Article	IF	Citations
1	Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2023, 21, 1523-1532.e1.	4.4	31
2	A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clinical Gastroenterology and Hepatology, 2022, 20, 658-673.	4.4	55
3	Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. International Journal of Obesity, 2022, 46, 486-493.	3.4	12
4	Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver International, 2022, 42, 374-383.	3.9	14
5	Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management. Chemotherapy, 2022, 67, 152-163.	1.6	10
6	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	1.6	1
7	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	4.9	33
8	Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient. Journal of Diabetes and Its Complications, 2021, 35, 107891.	2.3	1
9	Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Reports, 2021, 3, 100262.	4.9	15
10	Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients. Aging Clinical and Experimental Research, 2021, 33, 3321-3331.	2.9	6
11	Reply to the Letter: "Low levels of transaminase and mortality risk in older people with special reference to sarcopenia― Aging Clinical and Experimental Research, 2021, 34, 217.	2.9	2
12	Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver. Cell Death and Disease, 2021, 12, 1092.	6.3	5
13	The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon. Clinical Neurology and Neurosurgery, 2020, 197, 106166.	1.4	1
14	Lipophagy Impairment Is Associated With Disease Progression in NAFLD. Frontiers in Physiology, 2020, 11, 850.	2.8	70
15	An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase. American Journal of Physiology - Renal Physiology, 2020, 319, G469-G480.	3.4	26
16	Steroid-refractory immune related hepatitis may hide viral re-activation. Future Science OA, 2020, 6, FSO614.	1.9	2
17	Voltammetric analysis for distinguishing portal hypertension-related from malignancy-related ascites: A proof of concept study. PLoS ONE, 2020, 15, e0233350.	2.5	5
18	Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism, 2020, 21, 866-884.	1.2	8

#	Article	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0233350.		O
20	Title is missing!. , 2020, 15, e0233350.		0
21	Title is missing!. , 2020, 15, e0233350.		0
22	Title is missing!. , 2020, 15, e0233350.		0
23	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	2.2	2
24	Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. European Journal of Internal Medicine, 2019, 65, 51-57.	2.2	24
25	Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. Digestive and Liver Disease, 2019, 51, 1330-1336.	0.9	19
26	Diagnostic value of Virtual Touch Quantification (VTQ \hat{A}^{\otimes}) for differentiation of hemangiomas from malignant focal liver lesions. Medical Ultrasonography, 2019, 21, 371.	0.8	5
27	Exhaled breath analysis in hepatology: State-of-the-art and perspectives. World Journal of Gastroenterology, 2019, 25, 4043-4050.	3.3	14
28	Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients. European Journal of Internal Medicine, 2018, 54, 60-64.	2.2	4
29	Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 925-930.	3.6	67
30	Impairment of GH/IGF-1 Axis in the Liver of Patients with HCV-Related Chronic Hepatitis. Hormone and Metabolic Research, 2018, 50, 145-151.	1.5	12
31	The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Archives of Medical Science, 2018, 14, 701-706.	0.9	25
32	Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-9.	1.9	14
33	Lack of reduction in serum alphaâ€fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virusâ€related cirrhosis. Journal of Viral Hepatitis, 2018, 25, 1493-1500.	2.0	6
34	Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. World Journal of Gastroenterology, 2018, 24, 4835-4845.	3.3	31
35	Platelet count may impact on lysosomal acid lipase activity determination in dried blood spot. Clinical Biochemistry, 2017, 50, 726-728.	1.9	14
36	Breathâ€print analysis by eâ€nose may refine risk stratification for adverse outcomes in cirrhotic patients. Liver International, 2017, 37, 242-250.	3.9	11

#	Article	IF	Citations
37	Reelin expression in human liver of patients with chronic hepatitis C infection. European Journal of Histochemistry, 2017, 61, 2745.	1.5	18
38	Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials. Current Pharmaceutical Design, 2017, 23, 870-878.	1.9	11
39	The Liver as Another Possible Target Organ for $\langle i \rangle$ Bacillus cereus $\langle i \rangle$ Infection. Case Reports in Infectious Diseases, 2016, 2016, 1-3.	0.5	1
40	Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study. Scientific Reports, 2016, 6, 25337.	3.3	41
41	The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scandinavian Journal of Gastroenterology, 2016, 51, 967-973.	1.5	20
42	Lysosomal acid lipase activity is reduced in patients with cirrhosis and associated with surrogate indices of portal hypertension. Digestive and Liver Disease, 2016, 48, e34.	0.9	0
43	Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology. PLoS ONE, 2016, 11, e0156113.	2.5	21
44	Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances. Reviews on Recent Clinical Trials, 2016, 11, 238-252.	0.8	3
45	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology, 2016, 8, 949.	2.0	5
46	Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. World Journal of Hepatology, 2016, 8, 1244.	2.0	6
47	Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 1.	1.1	6
48	Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation. Journal of Clinical Pathology, 2015, 68, 883-890.	2.0	13
49	Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. Expert Review of Anticancer Therapy, 2015, 15, 971-976.	2.4	12
50	Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy. Metabolic Brain Disease, 2015, 30, 1445-1452.	2.9	11
51	Hepatic tollâ€like receptor 4 expression is associated with portal inflammation and fibrosis in patients with <scp>NAFLD</scp> . Liver International, 2015, 35, 569-581.	3.9	73
52	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World Journal of Gastroenterology, 2015, 21, 7412.	3.3	42
53	Hepatitis A virus in a medical setting in Madagascar: a lesson for public health. New Microbiologica, 2015, 38, 119-20.	0.1	0
54	Letter to the Editor Haemorrhoidal disease in severe portal hypertension: a combined approach with transjugular intrahepatic portosystemic shunt (TIPS) and transanal haemorrhoidal dearterialization (THD). Archives of Medical Science, 2014, 1, 195-196.	0.9	3

#	Article	IF	CITATIONS
55	Liver Toxicity in Colorectal Cancer Patients Treated with First Line Folfiri-Containing Regimen: a Single Institution Experience. Annals of Oncology, 2014, 25, iv536.	1.2	O
56	Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 376-385.	1.5	7
57	Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship. Journal of Viral Hepatitis, 2014, 21, e136-7.	2.0	1
58	Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.9	12
59	Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. BMC Gastroenterology, 2014, 14, 94.	2.0	4
60	Determinants of alanine aminotransferase levels in a large population from Southern Italy: Relationship between alanine aminotransferase and age. Digestive and Liver Disease, 2014, 46, 909-915.	0.9	16
61	Renal impairment and anemia during triple therapy. Journal of Hepatology, 2014, 60, 1099-1100.	3.7	1
62	Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World Journal of Gastroenterology, 2014, 20, 2825.	3.3	31
63	The potential diagnostic role of procalcitonin for bacteremia in a large cohort of solid cancer patients Journal of Clinical Oncology, 2014, 32, e20664-e20664.	1.6	0
64	Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 376-85.	1.5	4
65	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Internal and Emergency Medicine, 2013, 8, 509-520.	2.0	23
66	Risk factors for hospital readmission of elderly patients. European Journal of Internal Medicine, 2013, 24, 45-51.	2.2	72
67	Comparison of Disease Clusters in Two Elderly Populations Hospitalized in 2008 and 2010. Gerontology, 2013, 59, 307-315.	2.8	14
68	Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography. Archives of Medical Science, 2013, 4, 635-639.	0.9	8
69	Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease. Modern Pathology, 2012, 25, 576-589.	5.5	30
70	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1283-1288.	2.4	8
71	Distortion-Product Otoacoustic Emissions: A Useful Test for Monitoring Ototoxicity Induced by Pegylated Interferon and Ribavirin Treatment in Patients with Chronic Hepatitis C. International Journal of Immunopathology and Pharmacology, 2012, 25, 551-556.	2.1	1
72	Interleukinâ€28B (ILâ€28B) singleâ€nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCVâ€infected patients. Journal of Viral Hepatitis, 2012, 19, 650-653.	2.0	9

#	Article	IF	CITATIONS
73	Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology, 2012, 56, 2180-2187.	7.3	192
74	HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterology, 2012, 12, 162.	2.0	18
75	Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. Digestive and Liver Disease, 2012, 44, 674-680.	0.9	17
76	The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Supportive Care in Cancer, 2012, 20, 135-139.	2.2	21
77	A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood'. Aging Clinical and Experimental Research, 2012, 24, 559-60.	2.9	1
78	Angiogenic Cytokines in Patients Undergoing Antiviral Treatment for Chronic Hepatitis C Virus Infection. Journal of Interferon and Cytokine Research, 2011, 31, 207-210.	1.2	7
79	Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. European Journal of Internal Medicine, 2011, 22, 205-210.	2.2	88
80	Deep Vein Thrombosis, Inferior Vena Cava Interruption and Multiple Thrombophilic Gene Mutations. American Journal of the Medical Sciences, 2011, 342, 79-82.	1.1	7
81	Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study. Journal of Viral Hepatitis, 2011, 18, 393-399.	2.0	9
82	Gas exchanges and pulmonary vascular abnormalities at different stages of chronic liver disease. Liver International, 2011, 31, 525-533.	3.9	7
83	Blood glucose monitoring in the normal population: the PREDICA study. Acta Diabetologica, 2011, 48, 29-34.	2.5	1
84	Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. European Journal of Clinical Pharmacology, 2011, 67, 507-519.	1.9	255
85	Inâ€hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. International Journal of Geriatric Psychiatry, 2011, 26, 930-936.	2.7	32
86	The role of $\langle i \rangle S \langle j \rangle$ -adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opinion on Drug Safety, 2011, 10, 345-349.	2.4	15
87	Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge. World Journal of Gastroenterology, 2011, 17, 2580.	3.3	12
88	Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. World Journal of Hepatology, 2011, 3, 278.	2.0	42
89	Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver International, 2010, 30, 867-870.	3.9	40
90	Apoptosis and Autoimmunity Induced by Clodronate in Systemic Lupus Erythematosus Mononuclear Circulating Cells. International Journal of Immunopathology and Pharmacology, 2010, 23, 535-542.	2.1	3

#	Article	IF	Citations
91	Gene therapy and enhancement for diabetes (and other diseases): the multiplicity of considerations. Diabetes/Metabolism Research and Reviews, 2010, 26, 520-524.	4.0	6
92	Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. BMC Gastroenterology, 2010, 10, 21.	2.0	23
93	In-Hospital Death and Adverse Clinical Events in Elderly Patients According to Disease Clustering: The REPOSI Study. Rejuvenation Research, 2010, 13, 469-477.	1.8	38
94	Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. European Journal of Internal Medicine, 2010, 21, 516-523.	2.2	51
95	Complication Related to Medical Conditions. , 2010, , 3-11.		0
96	Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients. Medical Microbiology and Immunology, 2009, 198, 13-18.	4.8	5
97	Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon αâ€2a and ribavirin: a multicentric study. Liver International, 2009, 29, 1479-1484.	3.9	17
98	A mocking finding: portal cavernoma mimicking neoplastic mass: first sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation. European Journal of Gastroenterology and Hepatology, 2009, 21, 233-236.	1.6	4
99	Westernization of the Filipino population resident in Rome: obesity, diabetes and hypertension. Diabetes/Metabolism Research and Reviews, 2008, 24, 364-370.	4.0	13
100	Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature. Journal of Experimental and Clinical Cancer Research, 2008, 27, 28.	8.6	5
101	Menarche in type 1 diabetes is still delayed despite good metabolic control. Fertility and Sterility, 2008, 90, 1875-1877.	1.0	33
102	The PTPN22 1858T Gene Variant in Type 1 Diabetes Is Associated With Reduced Residual Â-Cell Function and Worse Metabolic Control. Diabetes Care, 2008, 31, 1214-1218.	8.6	35
103	Association Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A First Message Should Pass. American Journal of Gastroenterology, 2008, 103, 3036-3038.	0.4	24
104	Peripheral Graft Infection due to Staphylococcus aureus without Abnormal Findings by 99mTc-HMPAO-Labeled-Leukocyte Scan. Internal Medicine, 2008, 47, 1941-1944.	0.7	0
105	Lower schooling, higher hepatitis C virus prevalence in Italy: An association dependent on age. Journal of Clinical Virology, 2007, 40, 168-170.	3.1	4
106	Raised C-reactive protein levels in patients with recent onset type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2007, 23, 211-214.	4.0	14
107	Percutaneous ultrasound-guided ablation of BW7756-hepatoma using ethanol or acetic acid in a rat model. BMC Gastroenterology, 2007, 7, 45.	2.0	2
108	Portal Diameter in the Diagnosis of Esophageal Varices in 266 Cirrhotic Patients: Which Role?. Ultrasound in Medicine and Biology, 2007, 33, 506-511.	1.5	12

#	Article	IF	CITATIONS
109	Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon. Clinical Immunology, 2006, 118, 229-232.	3.2	21
110	Blood ketone bodies in patients with recent-onset type 1 diabetes (a multicenter study). Pediatric Diabetes, 2006, 7, 223-228.	2.9	29
111	Left common and right internal carotid artery occlusion - color-coded duplex sonography and magnetic resonance angiography findings. European Journal of Neurology, 2006, 13, 423-424.	3.3	3
112	Associations between the IGF system and inflammatory markers in inflammatory bowel disease: authors' reply. Alimentary Pharmacology and Therapeutics, 2006, 23, 554-555.	3.7	2
113	Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease. Histopathology, 2006, 48, 822-830.	2.9	6
114	Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes/Metabolism Research and Reviews, 2006, 22, 274-283.	4.0	94
115	Metabolic Factors Affecting Residual Beta Cell Function Assessed by C-Peptide Secretion in Patients with Newly Diagnosed Type 1 Diabetes. Hormone and Metabolic Research, 2006, 38, 668-672.	1.5	22
116	Glucose Abnormalities in Patients With Hepatitis C Virus Infection: Epidemiology and Pathogenesis: Response to Lecube et al Diabetes Care, 2006, 29, 2558-2559.	8.6	2
117	Chemotherapy-Induced Steatohepatitis in Colorectal Cancer Patients. Journal of Clinical Oncology, 2006, 24, 5467-5467.	1.6	23
118	lloprost enhances portal flow velocity and volume in patients with systemic sclerosis. In Vivo, 2006, 20, 377-80.	1.3	5
119	An unusual post-traumatic case of extrahepatic bile duct compression. Mount Sinai Journal of Medicine, 2006, 73, 1093-4.	1.9	1
120	Isolated Hepatocytes versus Hepatocyte Spheroids: In Vitro Culture of Rat Hepatocytes. Cell Transplantation, 2005, 14, 397-401.	2.5	16
121	Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2005, 21, 1063-1071.	3.7	48
122	Retroperitoneal Fibrosis and Ankylosing Spondylitis: Which Links?. Seminars in Arthritis and Rheumatism, 2005, 35, 43-48.	3.4	16
123	Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes/Metabolism Research and Reviews, 2005, 21, 271-275.	4.0	41
124	Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. Clinical Rheumatology, 2005, 24, 381-387.	2.2	33
125	Low Levels of 25-hydroxyvitamin D3and 1,25-dihydroxyvitamin D3in Patients with Newly Diagnosed Type 1 Diabetes. Hormone and Metabolic Research, 2005, 37, 680-683.	1.5	176
126	Treatment of Cryptosporidiosis in Immunocompromised Hosts. Chemotherapy, 2005, 51, 193-196.	1.6	59

#	Article	IF	Citations
127	Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. International Immunopharmacology, 2005, 5, 437-459.	3.8	41
128	Iloprost: an adjunctive approach to chronic viral hepatitis treatment. Medical Hypotheses, 2005, 64, 46-52.	1.5	4
129	Improved Hepatic Perfusion After Iloprost Infusion in Patients with HCV Chronic Infection: A Pilot Study with Possible Therapeutic Implications. Journal of Interferon and Cytokine Research, 2004, 24, 297-300.	1.2	4
130	The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection. Current Pharmaceutical Design, 2004, 10, 2081-2092.	1.9	23
131	Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis. Acta Biomedica, 2004, 75, 69-73.	0.3	3
132	Hemodynamic effects of a prostacyclin analog (iloprost) on portal flow velocity and volume and visceral artery circulation in patients with lower limb arteriopathy. Ultrasound in Medicine and Biology, 2003, 29, 209-213.	1.5	9
133	Guest Editorial. Diabetic Medicine, 2003, 20, 871-872.	2.3	8
134	GH-resistance in different stages of chronic liver disease. Journal of Hepatology, 2003, 38, 67-68.	3.7	77
135	Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease. Journal of Hepatology, 2003, 38, 68.	3.7	0
136	TNF- $\hat{l}\pm$ and Growth Hormone Resistance in Patients with Chronic Liver Disease. Journal of Interferon and Cytokine Research, 2003, 23, 229-235.	1.2	30
137	Severe Liver Dysfunction After Raltitrexed Administration in an HCV-Positive Colorectal Cancer Patient. Cancer Investigation, 2003, 21, 162-163.	1.3	9
138	The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Annals of Oncology, 2003, 14, 1468-1476.	1.2	135
139	S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Research, 2003, 23, 5173-9.	1.1	29
140	Case Report: Liver Cirrhosis After Prolonged Therapy with IFN-α plus Interleukin-2 in a Metastatic Renal Cancer Long-Term Survivor. Journal of Interferon and Cytokine Research, 2002, 22, 683-688.	1.2	4
141	Development of a New Bioartificial Liver Using a Porcine Autologous Biomatrix as Hepatocyte Support. ASAIO Journal, 2002, 48, 592-597.	1.6	5
142	Viral cirrhosis with chronic right heart failure and cardiac liver sclerosis: a hypothesis on the differentiation between the two diseases through pulsed Doppler sonography examination. Medical Hypotheses, 2002, 59, 591-593.	1.5	1
143	Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. Journal of Physiology and Biochemistry, 2000, 56, 91-99.	3.0	17
144	Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-I. American Journal of Physiology - Renal Physiology, 2000, 279, G319-G324.	3.4	34

#	Article	IF	CITATION
145	Effect of insulin-like growth factor I on in vivo intestinal absorption of d-galactose in cirrhotic rats. American Journal of Physiology - Renal Physiology, 1999, 276, G37-G42.	3.4	27
146	Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. Journal of Hepatology, 1998, 28, 122-131.	3.7	80
147	Low doses of insulin-like growth factor-l improve nitrogen retention and food efficiency in rats with early cirrhosis. Journal of Hepatology, 1997, 26, 191-202.	3.7	53
148	Percutaneous transhepatic stenting by wallstents of portal vein and bile duct stenoses caused by immunoblastic sarcoma in a liver transplantation. CardioVascular and Interventional Radiology, 1994, 17, 210-213.	2.0	18
149	Effectiveness of Aprotinin in Orthotopic Liver Transplantation. Seminars in Thrombosis and Hemostasis, 1993, 19, 292-296.	2.7	22
150	Reversal of basal ganglia hyperintensity on T1-weighted images on MRI after successful orthotopic liver transplantation (OLT). Hepatology, 1993, 18, 748.	7.3	1
151	Intravenous infusion of diarginylinsulin, an insulin analogue: Effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metabolism: Clinical and Experimental, 1992, 41, 540-544.	3.4	17
152	Indirect pathway of liver glycogen synthesis in humans is predominant and independent of betaâ€adrenergic mechanisms. Clinical Physiology, 1992, 12, 641-652.	0.7	1
153	Quantitation of Forearm Glucose and Free Fatty Acid (FFA) Disposal in Normal Subjects and Type II Diabetic Patients: Evidence Against an Essential Role for FFA in the Pathogenesis of Insulin Resistance*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 893-898.	3.6	28